Cingulate starts final FDA-required study for lead ADHD asset CTx-1301; raises $10M+

Cingulate Inc.

Commenced final FDA-required food effect study for CTx-1301 (dexmethylphenidate) for ADHD; data readout expected by end of 2024.
Raised over $10M in additional capital since mid-August 2024, including 58% from at-the-market facility.
Received notification from Nasdaq that company is now in compliance with listing requirements.
Reinstated CEO/COO/CFO base salaries to original levels ($503K, $424K, $350K) after late-2023 reductions.
Cost containment measures have saved approximately $1.45M cumulatively; headcount remains ~40% below 2023 levels.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.